MGTX News & Events

MeiraGTx signed an exclusive license agreement with ZipBio, a biotechnology company pioneering AI-driven protein therapeutics. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for Geographic Atrophy, targeting the complement pathway. The licensing deal combines MeiraGTx's vector design, clinical development, and in-house manufacturing of genetic medicines, and ZipBio's de novo-designed protein therapeutics, developed using its COMPACT generative AI platform. The agreement includes upfront, as well as potential milestone and royalty payments. Financial terms were not disclosed. COMPACT is ZipBio's proprietary generative AI platform for designing protein therapeutics beyond the limits of conventional biologics.

As of September 30, 2025, MeiraGTx had cash and cash equivalents of approximately $14.8 million, as well as $2.8 million in receivables due from Johnson & Johnson Innovative Medicine and $9.0 million in tax incentive receivables. Together with the $75.0 million upfront cash payment from Lilly, and the $22.0 million received to date in the fourth quarter 2025 and the remaining $150.0 million from the anticipated closing of the strategic collaboration with Hologen, the Company believes that it will have sufficient capital to fund operating expenses and capital expenditure requirements into the second half of 2027 and to repay its debt obligation of $75.0 million to Perceptive Credit Holdings III, LP (due in August 2026). This estimate does not include the $135.0 million in potential near-term cash consideration from Lilly upon the achievement of certain development and regulatory approval milestones, or the $285.0 million in milestones the Company is eligible to receive under the asset purchase agreement upon first commercial sale of bota-vec in the United States and in at least one of the United Kingdom, France, Germany, Spain and Italy, for completion of the transfer of certain manufacturing technology to Johnson & Johnson Innovative Medicine and upon regulatory approval of a Johnson & Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of bota-vec.